Press

Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

Jun 22 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis, and Imaging of Diseases and Disorders.” The new patent claims cover the Company’s portfolio drug SPU-21,…

PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.

Jun 20 • 3 min read

PharmaTher Holdings Ltd. (OTCQB: PHRRF / CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has entered into a collaboration agreement with Vitruvias Therapeutics, Inc. (“Vitruvias”), a leading U.S. based specialty generic pharmaceutical company, for the commercialization of the Company’s KETARX™ (racemic ketamine) products in the U.S. In partnership with Vitruvias, KETARX™…

Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001

Jun 20 • 4 min read

Delix Therapeutics, a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the completion of dosing of the first cohort of subjects in its phase I clinical trial of lead candidate, DLX-001, a non-hallucinogenic psychoplastogen. Key results from first cohort include: “These results represent another significant milestone, not only for…

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

Jun 16 • 4 min read

Delix Therapeutics, a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Aaron Koenig as Chief Medical Officer. Dr. Koenig will oversee Delix’s clinical development programs, team build-out, and broader development strategy as the company advances its psychoplastogen platform of novel disease-modifying therapeutics for serious psychiatric, neurological, and neurodegenerative…

Nue Life Health Announces $1.9M Financing, Opening of its App to Support all Patients Undergoing Ketamine Therapies and the Appointment of Dr. Drummond as CMO

Jun 16 • 7 min read

Nue Life Health, a leading mental wellness company supporting patients undergoing psychedelic therapies, announced today the completion of a $1.9m financing by existing investors to support its next phase of evolution. In this next phase Nue Life will make its revolutionary “Nue app” and its “Nue score” available for free to any patient undergoing ketamine therapy. Since…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435